Nilotinib in Cognitively Impaired Parkinson Disease Patients 001
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This pilot study will test Nilotinib's ability to alter the abnormal protein build up in
Parkinson disease and Diffuse Lewey Body Disease patients . Patients will receive Nilotinib
at different doses for 6 months. Patients will then be tested to see if there is change in
three areas: 1) has the disease symptoms changed. 2) has levels of a specific misfolded
protein changed in the fluid around their brain and spine. 3) Have inflammatory markers
changed in the patient's blood and fluid around their brain and spine. If successful, this
drug could be used to slow down or stop the progression of disorders that involve abnormal
collection of misfolded proteins. However, the main purpose of this pilot study is to check
for the safety of using this medication at this level.